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Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse
after allogeneic stem cell transplantation, and relatively few new agents have demonstrated
activity. Clofarabine is a novel nucleoside analog that has been associated with significant
clinical activity in relapsed pediatric B-ALL. We used low dose clofarabine and induced a re-
mission in a patient who relapsed in the skin and marrow after allogeneic transplant and
was refractory to nelarabine and report a near complete response, suggesting significant ac-
tivity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.
INTRODUCTION
Of the 4,000 cases of acute lym-
phoblastic leukemias (ALL)† diagnosed in
theUnitedStateseveryyear,onethirdoccur
in adults.AdultALLremains a difficultdis-
ease to cure in contrast with the cure rate of
almost 80 percent in children and adoles-
cents [1]. Front-line protocols often call for
aggressive therapy for high-risk patients
during induction, consolidation, and main-
tenance therapy. Allogeneic hematopoietic
stem cell transplantation is offered to eligi-
blepatientswiththepromiseofaprolonged
leukemiafreesurvival [1].Forpatientswho
relapse after transplantation or who are not
eligible for stem cell transplant due to lack
of an appropriate donor or comorbid med-
ical conditions, novel salvage therapies are
desperately needed [2]. Recently, two nu-
cleoside analogs, nelarabine and clofara-
bine, have been FDAapproved for patients
with relapsed or refractoryT-cell and B-cell
lymphocytic leukemia respectively [3-7].
Clofarabine is a novel purine nucleo-
side analog that has shown promise in early
phase II studies for pediatric patients with
B-ALL. The product of rationally designed
improvements to two older adenine nucleo-
sides, clofarabine is taken up into cells by
an active nucleoside transporter [8] and is
subsequently phosphorylated into nu-
cleotide analogues clofarabine 5’-mono-,
di-, and triphosphate, with clofarabine
triphosphatebeingtheactivemetabolite[9].
Clofarabine has been shown to have three
mechanisms of action in leukemia cells:
first, it is incorporated into DNA and im-
pairs DNAelongation and repair; second, it
isapotentinhibitorofribonucleotidereduc-
tase,depletingthenucleotidepoolprimarily
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MDS, myelodysplastic syndrome.ofdCTPanddATP;andthird, itmaydirectly
induceapoptosisbyalteringthemitochondr-
ial membrane and subsequently enabling re-
lease of cytochrome c [4].
InaphaseIIstudyofclofarabineinape-
diatric population with refractory B-ALL,
the response rate was 30 percent [5]. In the
adult population, an initial phase I study
showed that two of 13 patients responded
[7].InasubsequentphaseIIstudyinpatients
with refractory or relapsing ALL, acute
myelogenous leukemia (AML), and
myelodysplasticsyndrome(MDS),twoof12
patients withALL had responses [6]. In this
report, we describe a case wherein low-dose
weekly administration of clofarabine in-
duced a response in a patient with refractory
TcellALLwithprimarilycutaneousdisease.
CASE REPORT
JK is a 35-year-old male with precursor
T-lymphoblastic leukemia diagnosed in
2001 with a bone marrow blast immunophe-
notype of CD2+CD7+CD3+ cells with aber-
rant expression of CD13 and negative
staining for TdT and myeloperoxidase. His
karyotypic analysis was indicative of a 4;11
translocation involving the MLL gene at
11q23. He was induced and underwent allo-
geneic stem cell transplantation (SCT) from
his HLA-identical fraternal twin brother in
April 2002. He was in remission with lim-
ited skin chronic graft-vs.-host disease until
January 2003, when he relapsed and was
treated with ICE chemotherapy followed by
a donor lymphocyte infusion. He remained
in remission until February 2005, when he
developed nodular violacious skin lesions
which on biopsy revealed T-cells consistent
with his original leukemia. Full restaging in-
cluding bone marrow biopsy and cere-
brospinal fluid analysis were negative,
indicating an isolated skin recurrence. Re-
induction therapy was initiated with cy-
clophosphamide and gemcitabine but was
complicated by significant myelosuppres-
sion and renal insufficiency. He received a
brief course of systemic retinoid therapy
with bexarotene and spot electron beam irra-
diation for symptomatic improvement of
nodular disease on his face with rapid recur-
rence at the completion of radiation. He then
was treated with nelarabine in February
2006 and responded but developed worsen-
ing renal insufficiency.
He quickly developed recurrent nodular
tumors over his brow, around his right ear,
on his chest, and on his back and chest (Fig-
ure 1). On restaging in October 2006, the pa-
tient had no evidence of lymphadenopathy
or involvement of liver or spleen by CT
scan. A bone marrow biopsy revealed re-
lapse of known precursor-T lymphoblastic
leukemia involving 40 percent of the mar-
row. The cells were CD2+ CD7+ CD34+
HLA-DR+ CD3-. Flow cytometry of the
blood was negative for blasts with only oc-
casional reactive lymphocytes.At that time,
his leukocyte count was 2.0 with 64 percent
neutrophils and 35 percent lymphocytes, the
hematocrit was 24.5 and platelets were 52 x
103/dl. He initiated therapy with clofarabine
at 10 mg/m2 weekly for three consecutive
weeks every 28 days. Treatment schedule
Figure 1: Clinical response to clofara-
bine in patient with precursor T-ALL
with cutaneous involvement. A: At study
entry; B: After 2 cycles of clofarabine.
A B
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WBC
(103/mm3)
2.5
2.0
0.3
3.7
2.2
1.0
1.4
0.4
1.9
Creatinine
(mg/dl)
1.8
2.2
2.2
2.2
2.1
2.0
1.9
2.0
2.3
Clofarabine
dose
10 mg/m2
10 mg/m2
held
10 mg/m2
10 mg/m2
held
10 mg/m2
held
10 mg/m2
C1D1
C1D8
C1D15
C2D1
C2D8
C2D15
C3D1
C3D8
C4D1
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and toxicities are shown in Table 1. There
was no hepatic toxicity, and only mild fluc-
tuations of the creatinine were noted. Treat-
ment was held on the third week of the first
two cycles due to neutropenia.
After two cycles of clofarabine, the pa-
tient’s lesions regressed significantly as
shown in Figure 1. Cycle 3 was delayed due
to a hospitalization for herpetic esophagitis,
which resolved with acyclovir therapy. He
remains on weekly low-dose clofarabine
with ongoing response after three months.
His platelet count has been stable at
99,000/mm3. An unrelated donor has been
identified, and the patient will undergo a
second allogeneic stem cell transplant.
DISCUSSION
In this case report, we demonstrate the
efficacy and safety of weekly low dose clo-
farabine in a patient with relapsed and re-
fractory precursor T-ALL. Because
clofarabine is renally excreted, it has been
dosed with caution in patients with renal or
hepatic insufficiency [4]. In this case, clo-
farabine was successfully administered, al-
beit at a reduced dose, without worsening of
renal function or evidence of disproportion-
ate drug-related toxicity.
The observed response in this patient is
surprising, given the low dose and intermit-
tent scheduling [4]. Pharmacokinetics stud-
ies showed that intracellular concentrations
did not become saturated at doses less than
20 mg/m2; furthermore, despite an estimated
half-life of 24 hours, there was no evidence
of accumulation in doses less than 40
mg/m2/day. In vitro studies demonstrated
that breakthrough DNA synthesis occurs in
leukocytes derived from patients receiving
systemic doses less than 40 mg/m2, suggest-
ing suboptimal effect [10]. Consistent with
the predictions made by the in vitro data and
the pharmacokinetics of the drug, the clini-
cal trials have suggested better results with
higher doses. In particular, patients with re-
lapsed CLLwere treated with 2 mg/m2with-
out any responses observed (ILEX Products
Inc., personal communication). Neverthe-
less, it may be reasonable in patients with
more rapidly proliferating disorders to ad-
minister clofarabine at a lower dose using
this weekly schedule.
Lastly, we present this case report as the
first evidence for the efficacy of clofarabine
in treating primary or secondary cutaneous
lymphoma/leukemia. As mentioned above,
this patient had extensive involvement of the
skin with hisT-cell leukemia.The cutaneousChoi and Foss: Efficacy of clofarabine in T-acute lymphocytic leukemia 172
response was brisk with this low dose of clo-
farabine. One possible explanation for the
sensitivity of the patient’s tumor to low-dose
clofarabine is localization of the drug in the
skin, as was demonstrated in murine phar-
macokinetic models by Lindemalm et al.
Skin rash and palmoplantar erythrodysesthe-
sias have been reported in the clinical trials
in which clofarabine is administered on a
five-day schedule at higher doses, perhaps
related to retention of the drug in skin.
Based on this experience, it may be worth-
while to further investigate the efficacy of
low dose clofarabine in primary and second-
ary cutaneous malignancies.
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